Free press releases distribution network?

Agency / Source: Cision

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Patheon Announces Launch of Updated Quick to Clinic™ Program - Patheon announced the launch of its updated program Quick to Clinic™, making it the only CDMO to offer customers an accelerated 12-week clinical trial material program with stability data with a variety of flexible dosage forms - Patheon.com
Patheon Announces Launch of Updated Quick to Clinic™ Program

 

PRZOOM - /newswire/ - Durham, NC, United States, 2014/08/25 - Patheon announced the launch of its updated program Quick to Clinic™, making it the only CDMO to offer customers an accelerated 12-week clinical trial material program with stability data with a variety of flexible dosage forms - Patheon.com .

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Patheon, the pharmaceutical services business owned by DPx Holdings B.V., announced the launch of its updated program Quick to Clinic™, making it the only CDMO to offer customers an accelerated 12-week clinical trial material program with stability data with a variety of flexible dosage forms.

The Quick to Clinic™ offering includes a month of clinical trial stability studies, provides customers access to six flexible dosage forms and decreases the wait time from receipt of API for clinical trial materials for First in Human trials by one month. Patheon customers can now receive high-quality Phase I clinical trial materials in as few as 12 weeks and with stability data, delivering maximum speed without compromising quality.

The six Quick to Clinic™ dosage forms offered by Patheon include blend in capsule, API in capsule, blend in bottle, API in bottle, oral liquid and softgel.

With expansive resources and expertise, Quick to Clinic™ offers customers the ability to meet their unique scientific requirements with capabilities spanning from formulation development and manufacturing to clinical packaging and distribution.

“We are excited about the enhanced Quick to Clinic program and the benefit that it will provide to our customers,” says Mike Lehmann, President, PDS and Executive Vice President, Global Sales and Marketing, Patheon. “We are now the only CDMO that can offer customers a 12-week clinical trial program that delivers maximum speed, but does not compromise quality.”

Quick to Clinic™ was first launched in 2009, and Patheon has refreshed the program and expanded it to include its sites in Cincinnati, Ohio; Milton Park, U.K.; Tilburg, the Netherlands; and Toronto, Ontario.

About Patheon

Patheon (patheon.com) is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Patheon, a DPx Holdings B.V. business unit, encompasses the combined CMO capabilities and pharmaceutical product development services (PDS), as well as the Biosolutions and Biologics (BIO) business.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Cision

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Patheon Announces Launch of Updated Quick to Clinic™ Program

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Press Office - Patheon.com 
919-226-3200 media[.]patheon.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Cision securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Cision / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  NAKIVO, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Intrinsic Executive Search Ltd







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today